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Calmodulin (CaM) is a versatile Ca2+-sensor/transducer protein that modulates hundreds
of enzymes, channels, transport systems, transcription factors, adaptors and other struc-
tural proteins, controlling in this manner multiple cellular functions. In addition to its cap-
acity to regulate target proteins in a Ca2+-dependent and Ca2+-independent manner, the
posttranslational phosphorylation of CaM by diverse Ser/Thr- and Tyr-protein kinases has
been recognized as an important additional manner to regulate this protein by ﬁne-tuning
its functionality. In this review, we shall cover developments done in recent years in which
phospho-CaM has been implicated in signalling pathways that are relevant for the onset
and progression of diverse pathophysiological processes. These include diverse systems
playing a major role in carcinogenesis and tumour development, prion-induced encephal-
opathies and brain hypoxia, melatonin-regulated neuroendocrine disorders, hypertension,
and heavy metal-induced cell toxicity.
Introduction
Calmodulin (CaM) is a ubiquitous highly conserved Ca2+ sensor/transducer protein in all eukaryotic
cells. The Ca2+-dependent and Ca2+-independent functions of CaM are exerted by interacting and
controlling the activity of hundreds of enzymes, channels, transport systems, and a variety of
non-enzymatic proteins that are vital for the physiology of the cell [1–6]. As a Ca2+ sensor, CaM
transduces the oscillations of the intracellular concentration of this cation during cell activation by
growth factors, hormones, neuro-transmitters, and other effectors in meaningful cellular responses via
CaM-dependent proteins. In addition, diverse posttranslational modiﬁcations of CaM have been
recognized as a ﬁne-tuning mechanism by which CaM-dependent proteins are also modulated [7].
This includes phosphorylation [8], trimethylation of Lys115 [9], acetylation of the N-terminal alanine
residue [10], and carboxymethylation of aspartic and glutamic acids [11]. In this context, however, the
phosphorylation of CaM takes a central functional stage.
Since the ﬁrst report in 1983 by Plancke and Lazarides [12] describing the presence of
Ser-phosphorylated CaM in chicken brain and skeletal muscle, and the in vitro phosphorylation of
CaM by a preparation of phosphorylase b kinase, the biological importance of CaM phosphorylated at
Ser/Thr and Tyr residues has been recognized. These phosphorylated CaM forms differentially regu-
late, when compared with non-phosphorylated CaM, a great variety of CaM-dependent systems [8].
The different residues phosphorylated by Ser/Thr- and Tyr-protein kinases are shown in Figure 1. It
is important to remark the abundance of phosphorylatable residues located at the different EF-hands
(Thr26, Thr29, Thr44, Tyr99, Tyr138, Ser101, Thr117) although not all are within the sequence of the
Ca2+-binding sites, and in the ﬂexible central linker (Thr79, Ser81) connecting the N- and C-lobes of
the protein. This underscores the importance that these phosphorylated residues may have in modify-
ing the Ca2+-binding capacity of CaM and/or its interaction with target proteins. In recent years, new
progress has been done that helps to unravel the role of different phospho-CaM species in the control
of important physiological processes and its implication in different pathologies. This short review
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covers the advances done since our previous one in 2002 [8], but centred on the functionality of
phospho-Tyr-CaM and/or phospho-Ser/Thr-CaM in tumour cell biology, during neurological disorders, the
dysfunction of the vascular system particularly its role in hypertension, dysregulations of the neuroendocrine
melatonin system, and other cellular processes.
Phospho-Tyr-CaM in pathophysiology
Different phospho-Tyr-CaM species are implicated in signalling processes with pathophysiological implications.
The kinases so far known to participate in CaM phosphorylation are the EGFR, the insulin receptor, and
several non-receptor kinases such as c-Src and other Src family members, as well as Jak2 and p38Syk (see
Table 1).
CaM regulates many signalling pathways and cellular functions relevant for the biology of cancerous cells
[1]. It is expected, therefore, that different phospho-CaM species could be implicated in signalling routes
leading to tumour cell transformation. In this section, we discuss some processes in which phospho-Tyr-CaM
species are involved. There are several signalling systems very relevant for tumour cell proliferation and survival
that are regulated by CaM, and where phospho-Tyr-CaM could play prominent regulatory roles. This includes
the EGFR, the non-receptor tyrosine kinase c-Src, and the K-Ras/PI3K/Akt pathway.
CaM has been shown to interact with the cytosolic juxtamembrane region of the EGFR in a Ca2+-dependent
manner facilitating the ligand-dependent activation of the receptor in living cells [13–16]. As CaM is also a
good substrate for the EGFR [17], it was expected that phospho-Tyr-CaM could also interact with the receptor.
This indeed was the case [18,19], and the site of interaction of phospho-Tyr-CaM with the receptor was stab-
lished to be the same that the one for non-phosphorylated CaM located at the cytosolic juxtamembrane region
encompassing the sequence 645RRRHIVRKRTLRRLLQ660 [19]. The NMR-derived structure of a peptide corre-
sponding to the transmembrane (TM) and the cytosolic juxtamembrane ( JMcyt) segment, where the CaM-BD
is located, reconstituted in lipid bicelles shows that they form dimers and that the CaM-BD presents two helical
segments divided by a ﬂexible linker [20,21] (see Figure 2). This ﬂexible linker is important to understand the
expected bending of the JMcyt to facilitate electrostatic interaction with the phosphoinositide-rich negatively
charged inner leaﬂet of the plasma membrane to attain auto-inhibition of the EGFR in the absence of ligand
Figure 1. NMR structure of apo-CaM showing the amino acid residues known to be phosphorylated by diverse protein
kinases.
The ﬁgure depicts the NMR-derived structure of Ca2+-free CaM (apo-CaM) of Xenopus laevi showing the amino acid residues
known to be phosphorylated by diverse Ser/Thr- and Tyr-protein kinases. Note the location of the phosphorylatable residues
located at EF-hand I (Thr26 and Thr29), EF-hand III (Tyr99, Ser101) and EF-hand IV (Tyr138), and the ﬂexible inter-lobe linker
(Thr79 and Ser81). When phosphorylated, these residues may alter either the Ca2+-binding capacity of CaM or its interaction
with target CaM-binding proteins. The structure was obtained from PDB ID: 1DMO [87].
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[22]. In vitro studies show that phospho-Tyr-CaM enhances the ligand-dependent activation of the EGFR, and
this effect was observed as well using the phospho-mimetic CaM(Y99D/Y138D) mutant [19]. This suggests
that phospho-Tyr-CaM could be an intracellular co-activator of the EGFR more efﬁcient than non-
phosphorylated CaM in detaching the CaM-binding domain of the inner leaﬂet of the plasma membrane to
which is electrostatically bound [22], most provably due to the extra negative charges of phosphate. If this
Table 1 Pathophysiological implication of phospho-Tyr- and phospho-Ser/Thr-CaM
Phospho-CaM
species
Phosphorylated
residue
Action on
CaM 1Kinase
Exp.
evidence
Biological effect (Ref.)
Functional and pathological implications
p-Y-CaM DGNGY99ISAA Affect
EF-hand III
EGFR in vitro Phospho-Y-CaM enhances ligand-dependent
EGFR activation [19].
Cancer
GQVNY138EEFV Affect
EF-hand IV
c-Src In vivo The pleiotrophin/PTPRZ1 pathway enhances
CaM phosphorylation in SCLC [37].
Cancer
In silico Phospho-Y99-CaM binds to the SH2 domains
of the regulatory p85 subunit of PI3K activating
its catalytic p110 subunit and the K-RasB/PI3K/
Akt pathway [32,33]. Enhances proliferation, cell
survival, and resistance to apoptosis.
Cancer
In vitro
In vivo Hypoxia activates EGFR and c-Src enhancing
phospho-Y99-CaM [41,44].
Brain hypoxia
2SFKs In vitro Unknown effect of p-Y-CaM [8].
Leukaemia and lymphomas (?)
Jak2 In vivo Jak2/phospho-Tyr-CaM/NHE3 complex
activates Na+ reabsorption in kidney [48].
Hypertension
INSR In vitro Unknown effect of p-Y-CaM [92].
Diabetes (?)
p38Syk In vitro Unknown effect of p-Y-CaM [93].
p-S/T-CaM DGDGT26ITTK Affect
EF-hand I
CK2 In vitro PrP increases the catalytic activity of CK2
inducing CaM phosphorylation [60].
Spongiform encephalopathy
GTITT29KELG Affect
EF-hand I
In vitro Phospho-S101-CaM inhibits eNOS [62].
Decreased NO output result in lower
vasodilation. Phospho-mimetic CaM(T79D)
mutant decreases the Ca2+ sensitivity of SK2
channel [65]. Phospho-T-CaM diminishes SK
channel conductance [66].
Hypertension
GQNPT44EAEL Affect
EF-hand II
In vivo
KMKDT79DSEE Affect flexible
central linker
KDTDS81EEEI Affect flexible
central linker
In vitro Phospho-T29-CaM enhances uranium binding
[75,76].
Cell toxicity
NGYIS101AAEL Affect
EF-hand III
CaMK-IV In vitro Phospho-T44-CaM, phosphorylated by
CaMK-IV, inhibits CaMK-II [68]
GEKLT117DEEV Affect
EF-hand IV
PKCα In vitro Melatonin enhances phospho-S/T-CaM levels
[72].
Sleep disorders
In vivo
MLCK In vitro Unknown effect of p-T-CaM [77].
Myopathies (?)
PhK In vitro Unknown effect of p-S-CaM [12]
In vivo Glucogen metabolopathies (?)
1The kinases may phosphorylate one or more of the indicated residues.
2Includes other SFKs (v-Src, c-Fyn, c-Fgr).
CaM, calmodulin; CaMK-II/IV, CaM-dependent kinases II/IV; c-Src, cellular sarcoma kinase; EGFR, epidermal growth factor receptor; INSR, insulin
receptor; Jak2, Janus kinase 2; MLCK, myosin light-chain kinase; NHE3, Na+/H+ exchanger 3; PhK, phosphorylase b kinase; PrP, prion protein;
PTPRZ1, protein tyrosine-phosphatase receptor Z1; SCLC, small cells lung carcinoma; SFKs, Src-family kinases.
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assumption is correct, we may expect that phospho-Tyr-CaM could play a relevant role in EGFR-signalling,
particularly in tumours overexpressing this receptor.
The binding of CaM to c-Src was ﬁrst demonstrated in vitro and several potential CaM-binding sites in this
kinase identiﬁed [23,24]. The interaction of apo-CaM, and in lesser extent Ca2+/CaM, with c-Src induces a
robust increase in its autophosphorylation and kinase activity towards exogenous substrates, as demonstrated in
vitro and living cells [24,25]. In contrast with non-phosphorylated CaM, phospho-Tyr138-CaM does not
co-immunoprecipitate with c-Src [18]. However, the phospho-mimetic mutants CaM (Y99D/Y138D) and CaM
(Y99E/Y138E) strongly activate c-Src to the same level that non-phosphorylated CaM does, both in the absence
and presence of Ca2+ [24]. One possibility is that phospho-Tyr99 could be required for the activation process.
Nevertheless, it is not possible to infer from these experiments whether phospho-Tyr99-CaM and/or
phospho-Tyr99/Tyr138-CaM interact with c-Src in living cells. This remains a possibility that deserves to be
explored in the future. The identiﬁcation of potential CaM-binding sites in the proximal [24] and terminal [23]
regions of the SH2 domain of c-Src underscores the possibility that phospho-Tyr-CaM could interact with
these sites.
In pancreatic tumour cells, it was shown that the interaction of CaM with the terminal region of the SH2
domain of c-Src facilitates its recruitment to the Fas death receptor signalling complex in a FADD-independent
manner activating the c-Src/ERK pathway which promotes proliferation, cell survival, and resistant to apoptosis
[23]. In this context, a series of compounds that disrupt the interaction of CaM with the SH2 domain of c-Src
have been identiﬁed [26]. These compounds could be useful to prevent any potential action of CaM, and pos-
sibly phospho-Tyr-CaM, on c-Src signalling pathways. The possible action of phospho-Tyr-CaM on v-Src and
other Src-family kinases relevant in diverse lymphoblastic tumours is an interesting topic pending to be
Figure 2. NMR structure of the CaM-BD of the human EGFR reconstituted in lipid bicelles.
The ﬁgure depicts the NMR-derived dimeric structure of a TM-JMcyt peptide of the EGFR reconstituted in lipid bicelles
observed at different angles, and the interaction of phospho-Tyr99/Tyr138-CaM in the presence of Ca2+. The CaM-binding
domain (CaM-BD), site of interaction of non-phosphorylated CaM and phospho-Tyr-CaM, in both TM-JMcyt monomers is
highlighted indicating the amino acid residues corresponding to the sequence 645RRRHIVRKRTLRRLLQ660. For clarity, the
TM-JMcyt, including the CaM-BD segments, of each monomer is indicated by numbers. The structures were obtained from
PDB ID: 2M20 [20] (human EGFR TM-JMcyt) and 1CLL (human CaM).
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investigated, particularly since there is an intense cross-talk between the Ca2+ signal and many Src-family
kinases [25,27].
The K-Ras/PI3K/Akt pathway participates in cell proliferation and cell survival processes. K-RasB, but not
H-Ras or N-Ras, binds to and is down-regulated by CaM [28]. Also, PI3K is regulated by CaM upon binding
to its 110 kDa catalytic subunit (p110) [29] and the 85 kDa regulatory subunit (p85) [30].
Phospho-Tyr99-CaM, probably produced by a Src-family kinase, also interacts with the two SH2 domains of
the regulatory p85 subunit of PI3K, activating in this manner its catalytic p110 subunit [31]. It has been shown
that an extended form of phospho-Tyr99-CaM binds to the proximal SH2 domain (nSH2) of p85, while its
distal SH2 domain (cSH2) interacts with a collapsed conformation of phospho-Tyr99-CaM which carries in
addition K-Ras4B bound as determined in vitro by molecular simulation (see Figure 3). This tripartite inter-
action activates PI3K, since K-Ras4B also allosterically acts on its catalytic subunit. The transformation of PIP2
to PIP3 in the cell membrane upon activation of PI3K induces Akt binding to the membrane and activation,
transmitting downstream proliferative signals that are relevant for K-Ras-driven tumours [32,33].
Using an engineered chicken B-lymphocyte tumour DT-40 cell line with the two functional CaM genes
deleted, and one allele replaced by a CaM transgene repressible by tetracycline, it was shown that the expression
of the non-phosphorylatable CaM mutants, CaM (Y99F), CaM (Y138F), or CaM (Y99F/Y138F) in the absence
of endogenous wild-type CaM did not affect the growth and survival of the tumour cells. This suggests that
phosphorylation of CaM at tyrosine residues was not required for the initiation and progression of these
Figure 3. Tripartite PI3K/phospho-Tyr99-CaM/K-Ras4B complex.
The ﬁgure depicts a composite complex formed by phosphatidylinositol-4,5-bisphosphate-3-kinase (PI3K) interacting with
phopho-Tyr99-CaM (phospho-Tyr99-CaM) and K-Ras4B. To attain crystallization, the full-length p110α catalytic subunit (pink)
was fussed to a segment of the regulatory p85α subunit (blue) of PI3K comprising the proximal SH2 domain (nSH2) and the
inter-SH2 segment (iSH2) [88,89]. The distal SH2 domain (cSH2) is absent from the construct used for crystallization and it is
shown as a dashed box. Phospho-Tyr99-CaM (brown) in an extended conformation interacts with the proximal SH2 domain
(nSH2) of the regulatory p85α subunit of PI3K (blue), while a collapsed conformation of phospho-Tyr99-CaM (brown), which is
bound to K-Ras4B (green), interacts with its distal SH2 domain (cSH2) which is shown as a dashed box. K-Ras4B is
represented in its GDP-bound conformation, and phospho-Tyr99 (-Tyr-P) CaM is highlighted. This theoretical model is based
on reference [30], but it does not depict the actual interaction sites of the different proteins in the complex. The structures were
obtained from PDB ID: 4L1B (human PI3K, full-length p110α and 318–615 amino acid segment of p85α, at 2.6 Å X-ray
resolution [88,89]), 1CLL and 1CFC (human and Xenopus CaM at 1.7 Å X-ray resolution and NMR-derived structure,
respectively [87,90]) and 4LDJ (human K-Ras4B at 1.15 Å X-ray resolution [91]).
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processes, although endogenous phospho-Tyr-CaM was detected in the conditional CaM-knockout cell line
before CaM down-regulation [34]. It is important to mention that these tyrosine-defective mutants were previ-
ously characterized and were found to be biologically active [35].
Pleiotrophin is a ligand of the tyrosine-phosphatase receptor PTPRZ1 that upon binding to its extracellular
domain induces dimerization. This phosphatase receptor is characterized by having two phosphatase sites,
although the distal one is generally inactive. The distal phosphatase site of one PTPRZ1 monomer blocks the
proximal active site of the apposed monomer, suppressing in this manner its activity [36]. As a consequence,
pleiotrophin enhances the protein tyrosine phosphorylation level in the cell, and consequently it was shown
that the pleiotrophin/PTPRZ1 pathway enhances CaM phosphorylation in SCLC cells [37]. Whether or not
PTPRZ1-mediated tumour progression directly correlates with phospho-Tyr-CaM levels remains unknown.
Phospho-Tyr-CaM also participates in signalling processes relevant in the regulation of the vascular tone. In
agreement with the stimulatory action of phospho-Tyr-CaM on nNOS, phospho-Tyr-CaM and the phospho-
mimetic mutant CaM (Y99E/Y138E) also enhanced, albeit in minor degree, the catalytic activity of the eNOS
isoform when assayed in vitro, when compared with wild-type non-phosphorylated CaM [38]. In contrast,
phospho-Tyr-CaM and the phospho-mimetic mutant CaM (Y99D/Y138D) slightly inhibited bovine brain
PDE1 when compared with wild-type non-phosphorylated CaM [38]. However, bovine hearth PDE was inhib-
ited in vitro by phospho-Tyr-CaM in a larger extent, as was reported earlier [39]. Moreover, the phospho-
mimetic CaM(Y99E) mutant signiﬁcantly inhibited eNOS in vitro, while no signiﬁcant effect was found on the
activity of nNOS or iNOS [40]. Overall, these observations suggest that the action of phospho-Tyr-CaM on
NOS depends on the enzyme isoform, its tissular origin, and provably the phospho-Tyr residue of CaM
involved. This underscores the existence of a great variety in regulatory mechanisms controlling
CaM-dependent NO output implicated in vascular relaxation.
During experimental hypoxia of the brain, activation of the EGFR and c-Src [41,42] was observed. This leads
to enhanced CaM phosphorylation at Tyr99 in the cerebral cortex and brain nuclei, particularly mediated by
c-Src [43]. Phospho-Tyr99-CaM activates nNOS increasing the production of NO, and this potentially acceler-
ates neuronal cell death. Puzzlingly, addition of an nNOS inhibitor before the onset of hypoxia prevents
phospho-Tyr-CaM accumulation, suggesting that NO regulates EGFR and/or c-Src activation and hence the
CaM phosphorylation process [41,44]. This is consistent with the biphasic regulation that NO exerts on EGFR
activation [45,46].
Essential hypertension is a widespread heterogeneous illness in which a major pathophysiological factor is
the inability of the kidney to excrete sodium at normal blood pressure. This results in altered ﬂuid balance and
increased arterial resistance that affect the correct function of many organs [47]. The Na+/H+-exchanger (NHE)
plays a central role in Na+ reabsorption in the kidney proximal tubular system. It was demonstrated in cultured
podocytes that NHE1 is regulated by CaM, which is Tyr-phosphorylated by Jak2, a process in which the EGFR
also plays an important role [48]. In normal physiological conditions, Ang-II (angiotensin-II) activates this
exchanger promoting Na+ retention and increasing the arterial blood pressure. Moreover, oxidative stress
up-regulates the Ang-II receptor AT1R, inducing enhanced Jak2-induced CaM phosphorylation and formation
of the Jak2/phospho-Tyr-CaM/NHE3 complex, exacerbating Na+ retention leading to hypertension [49].
Phospho-Ser/Thr-CaM in pathophysiology
The best-studied Ser/Thr-kinase participating in CaM phosphorylation is CK2 (casein kinase 2), although other
kinases, such as PhK, CaMK-IV, PKCα, and MLCK, also phosphorylate this protein. Phospho-Ser/Thr-CaM
also participates in signalling pathways relevant in several diseases (see Table 1). In this section, some of these
processes are discussed.
The ubiquitous kinase CK2 plays many functional roles phosphorylating a variety of protein substrates, and
is implicated in cell viability and progression of the cell cycle [50]. The phosphorylation of CaM by CK2
occurs by the isolated catalytic α- and α0-subunits as demonstrated in vitro, while the N-terminal region of its
regulatory β-subunit exerts an inhibitory effect [51,52]. CaM directly interacts with the β-subunit of CK2, and
the C-terminal of CaM is implicated in the inhibitory effect of this subunit, as well as in the activation
mediated by polybasic peptides [53]. It is expected, therefore, that the holoenzyme is unable to phosphorylate
CaM. This was consistent with a report showing that the construct CK2α2
1–335 β2 does not phosphorylate CaM,
although the CK2α0-derived holoenzymes phosphorylated CaM when poly-Lys was present, while only weak
phosphorylation was observed in its absence [54]. The absolute requirement of a basic polypeptide, including
poly-Lys, for the phosphorylation of CaM by CK2 was earlier reported [55]. In ﬁbroblasts, serum induces an
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unbalanced overexpression of the CK2 α0-subunit without the corresponding expression of its β-subunit. It has
been stablished that the former subunit acts as an oncogene, and in concert with H-Ras has transforming cap-
acity. This is accompanied by increased cell proliferation rate and CaM phosphorylation in cultured cells due
to the unabated excess of CK2 α0-subunit [56]. This suggests that phospho-CaM could play a role in the trans-
formation process. Nevertheless, it cannot be excluded that other CK2 α0-subunit-substrates are also involved
in the transformation process. Interestingly, the SH3 domain of the protein HS1 directly interacts with the CK2
α-subunit in vitro inhibiting CaM phosphorylation and expected H-Ras-mediated transformation [57]. This
could open the possibility of using peptides derived from the SH3 domain of HS1 as potential therapeutics to
inhibit tumour transformation.
Transmissible spongiform encephalopathies from animals and human are produced by infecting agents
denoted prions. These agents are misfolded conformers of the host-coded glycoprotein PrP, which is able to
interact and to induce non-reversible conformational changes in normal counterpart protein molecules generat-
ing the pathological accumulation of the so-called disease-associated protein PrPd in the brain. This process
produces neural vacuolation, astrocytosis, and neurodegeneration leading to serious neurological dysfunctions
and patient death. Apparently, mutation of PrP can also favour or induce disease in the absence of an external
infective agent [58,59]. CK2 is able to phosphorylate PrP at Ser154 in vitro [60], and conversely recombinant
bovine PrP binds with high afﬁnity to the catalytic α/α0-subunits of CK2. This interaction increases the catalytic
activity of CK2 inducing CaM phosphorylation, and counteracts the inhibitory role that exerts its β-subunit
[61]. As CK2 and CaM are both abundant in the brain, this opens the possibility that increased activity of this
enzyme in spongiform encephalopathies and accumulation of phospho-CaM could play a role in the disease.
CK2 has been shown to phosphorylate several CaM residues, primarily affecting Thr79, Ser81, Ser101, and
Thr117, although phosphorylation of Ser81 prevents subsequent phosphorylation of Thr79 [8,53].
CK2-phosphorylated CaM inhibits eNOS activity as mentioned earlier, and the phospho-Ser101 residue is
likely to participate in the inhibition of eNOS [62]. The down-regulation of eNOS in endothelial cells by
CK2-phosphorylated CaM could have profound consequences in NO output and hence its vasodilatory cap-
acity leading to higher arterial blood pressure. It would be interesting to investigate whether this system is
altered in hypertensive individuals.
CaM is constitutively bound to the C-terminal of the subunits forming homo-tetrameric small-conductance
Ca2+-activated K+ (SK) channels [63] (see Figure 4), transducing in this manner the Ca2+ signal and opening
the channel pore [64]. The CaM/SK channel also forms a multimeric complex with CK2 and PP2A reversibly
regulating CaM phosphorylation levels. CK2 phosphorylates CaM only when the channel is closed [65].
Moreover, co-expression of SK2 channels with the phospho-mimetic CaM(T79D) mutant decreases the Ca2+
sensitivity of the channel, suggesting that phosphorylation of Thr79 by CK2 controls this process [65]. To
clarify matters, in the latter work Thr79 was mislabelled as Thr80. This is the position corresponding to full-
length CaM counting the N-terminal Met residue, which is not present in the mature protein. It has been
shown that up-regulated CK2 in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats
increases the level of CaM phosphorylation, and phospho-CaM diminishes SK channel conductance altering
the excitability of presympathetic neurons [66]. PIP2 plays an important role mediating SK channels activation
by CaM, as its binding site is located in the interphase of CaM/SK interaction. Moreover, phosphorylation of
Thr79 by CK2 reduces the afﬁnity for PIP2 inducing greater inhibition of the channel [67]. These ﬁndings
suggest that CK2-phosphorylated CaM, upon regulating SK channels, could intervene in the neural control of
dysregulated vessels implicated in essential hypertension.
Brain hypoxia also activates CaMK-IV via c-Src, and the former activates the transcription factor CREB
phosphorylating Ser133 enhancing the expression of pro-apoptotic proteins which initiate hypoxic neural cell
death [42,43]. In contrast with the case of CaMK-II that poorly phosphorylates CaM, CaMK-IV is able to efﬁ-
ciently phosphorylate CaM at Thr44, which is located in the proximal region of the second EF-hand Ca2+-
binding site. Moreover, the authors of this report also demonstrated that CaM phosphorylated by CaMK-IV
inhibits CaMK-II activity, when compared with non-phosphorylated CaM [68]. However, the action of
phospho-Thr44-CaM on CaMK-IV itself was not reported.
Melatonin (5-methoxy-N-acetyltryptamine) is a neurohormone mainly synthesized and secreted by the
pineal gland, also named epiphysis, located in the epithalamus between the two brain hemispheres, but extra
pineal tissues also synthesize melatonin. This hormone controls the cyclic 24-h circadian rhythm, and plays
many physiological functions in the organism, modulating, for example, the immune, neural, and cardiovascu-
lar systems, and exerting antioxidant actions among many other functions [69]. The melatonin receptor MT2 is
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a GPCR that is involved in many sleep and neuropsychiatric disorders, including insomnia, anxiety, and
depression. Therefore, melatonin and other agonists of this receptor have been used to treat these disorders
[70,71]. Melatonin has been shown to stimulate, at very low concentration, the phosphorylation of CaM
mediated by PKCα in the presence of the phorbol ester PMA in an in vitro reconstituted system as well as in
cultured cells [72]. In this process is implicated the downstream MAPK pathway, as determined using speciﬁc
inhibitors blocking melatonin-induced CaM-phosphorylation. The authors of this work suggested that high
serum melatonin levels during the dark phase of the circadian cycle may increase phospho-Ser/Thr-CaM con-
centration, down-regulating in this manner key CaM-dependent target enzymes sensitive to this phosphory-
lated modulator as previously described [8]. An intriguing possibility of interest to be studied in the future is
the occurrence of alterations of melatonin-induced CaM-phosphorylation in sleep disorders and other neuro-
psychiatric illness.
Heavy metals are very toxic, and some of their actions are due to its interaction with CaM by altering its
functionality [73,74]. Uranium chemical toxicity in living organisms is due, in part, to the interaction of the
uranyl ion with cellular proteins. The ﬁrst EF-hand Ca2+-binding motif of CaM has about thousand times
more afﬁnity for uranyl than for Ca2+, and in vitro studies demonstrated that phosphorylation of Arabidopsis
thaliana CaM by CK2 at a threonine in the ﬁrst Ca2+-binding loop, increases the uranyl afﬁnity at physiological
pH [75,76]. Another kinase known to phosphorylate the ﬁrst EF-hand Ca2+-binding site of vertebrate CaM at
Thr29, and in lesser extent Thr26, is MLCK [77]. It would be interesting to determine whether this kinase may
Figure 4. Cryo-EM structure of the human SK4/CaM complex.
The ﬁgure depicts the cryo-electron microscope-derived structure at 4.7 Å resolution of the human SK4/CaM complex in the
presence of Ca2+ (A). The four CaM molecules are highlighted in yellow (B). The four subunits of the SK4 channel (C) and the
four CaM molecules indicating the phosphorylation of Thr79, Ser81, and Ser101 by casein kinase 2 in the central ﬂexible linker
and the third EF-hand Ca2+-binding site, respectively, (D) are shown in isolation in different colours. The structure was obtained
from PDB ID: 6CNO [63].
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also contribute to this process. Uranium has an enormous toxic effect in cells of organisms contaminated with
this radioactive element. This may be due, in part, to its disrupting effect on Ca2+-binding to CaM preventing
in this manner its normal functionality, in addition to the lasting noxious effects exerted by this radioactive
element.
Perspectives
The diversity of phosphorylatable residues in CaM suggests that each one may have speciﬁc functionalities (see
Figure 1 and Table 1). As examples to be investigated in the future, it would be relevant to stablish whether
phosphorylation of Thr79 and Ser81 in the ﬂexible linker of CaM could play distinct or redundant roles in
modifying its ﬂexibility and therefore its capacity to rotate their N- and C-lobes, as this may be critical for its
interaction with target proteins. A CaM deletion mutant lacking Thr79 and Asp80 induces the loss of a partial
turn of the central α-helix resulting in the rotation of the C-lobe 220° with respect to the N-lobe positioning
both lobes in a cis orientation, when compared with the trans orientation in wild-type CaM [78]. This was
interpreted as to why this CaM mutant has decreased capacity to activate some CaM-binding enzymes, while
has little or no effect on others. Although this is a very likely possibility when performing in vitro assays, it is
not negligible to take in consideration that the absence of the phosphorylatable Thr79 residue in this mutant
could be relevant when considering its lack of phosphorylation in living cells. To stablish whether
phospho-Tyr99 and phospho-Tyr138 play a distinct role in modifying the Ca2+-binding capacity of CaM and/
or to determine its interaction with target proteins containing SH2 and/or PTB domains are points of interest.
Likewise, whether phosphorylation of both tyrosine residues in CaM is required or not to interact with some
target proteins is also a relevant point.
Another topic deserving special attention is whether, in addition to the case of PI3K, where the binding of
phospho-Tyr-CaM to the two SH2 domains of its p85 regulatory subunit has been stablished [32], there are
other proteins containing SH2 or PTB domains that may interact with phospho-Tyr-CaM regulating in this
manner their activities as suggested earlier [8]. This includes the SH2 domain of c-Src, where potential
CaM-binding sites have been identiﬁed [23,24]. This could be of particular importance, as this interaction may
explain how phospho-Tyr-CaM differentially regulates diverse signalling pathways when compared with non-
phosphorylated CaM. Furthermore, as CaM has the capacity to cluster different or identical subunits of a
variety of CaM-binding proteins and to interact with separate segments of the same polypeptide chain [2], it is
possible to visualize that phospho-Tyr-CaM could do the same, clustering two distinct SH2/PTB-containing
proteins or protein subunits if each one simultaneously bind to the phospho-Tyr99 and the phospho-Tyr138
residues.
A series of natural occurring CaM mutants, impairing Ca2+-binding, affect CaM-regulated ion channels in
the heart causing some arrhythmias, including the bradycardic long QT syndrome and idiopathic ventricular
ﬁbrillation [79–84]. One possibility worth to be explored in the future is whether mutations affecting phosphor-
ylatable CaM residues may also dysregulate ion channels in the heart and/or other organs. In this context, it
has been shown in Paramecium tetraurelia that changing Ser101 by a non-phosphorylatable residue in CaM
affects the ion channel-mediated motile response of the protozoa by acting on the low conductance Ca2+-
dependent K+ channel [85]. As CK2 phosphorylates CaM at different residues, including Ser101, it is tempting
to speculate whether the observed effect on this channel induced by the disabled CaM mutant could primarily
be due to the absence of phospho-Ser101-CaM. This is supported by the fact that Tetrahymena pyriformis
CaM, which has a phosphorylatable Thr instead of a Ser at position 101, restores the activity of dysfunctional
Ca2+-dependent K+ channels [85]. Curiously, two additional mutations simultaneously occurring in the CaM
(Ser101Phe) mutant that revert the phenotype are Asp80Tyr and Arg106Lys [86]. It would be interesting to
investigate whether phosphorylation of Tyr80 by a Src-family kinase occurs in this mutant, and if positive,
whether this phosphorylation is responsible for the suppressor activity of this triple mutant, as phospho-Tyr80
could mimic the effect of phospho-Ser101.
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